Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Compugen and Merck Serono Ventures to Jointly Establish New Biomarker Company Neviah Genomics Ltd

Published: Monday, June 25, 2012
Last Updated: Monday, June 25, 2012
Bookmark and Share
Neviah Genomic Ltd. to focus on the discovery and development of novel biomarkers for drug toxicity.

Compugen to utilize its predictive discovery technologies and Merck Serono Ventures to provide the initial funding. Neviah Genomics is the first company to be funded within the framework of Merck Serono's Israel Bioincubator program.

Merck Serono, a division of Merck, Darmstadt, Germany, and Compugen Ltd. announced the establishment of Neviah Genomics, a novel start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Neviah Genomics will be operating out of the Merck Serono Israel Bioincubator. Merck Serono Ventures will provide the initial funding for Neviah Genomics. Compugen will utilize certain proprietary predictive discovery technologies and receive an equity ownership in the new company and a right to royalties from potential future sales. Further financial details of the agreement were not disclosed.

Neviah Genomics represents the first investment within the framework of the recently formed Merck Serono Israel Bioincubator program. As such, Neviah Genomics will operate out of the state-of-the-art facilities inaugurated last month at Merck Serono's Israeli R&D center Inter-Lab, which offers 600 square meters of infrastructure and a wide range of incubation services for the program's new start-ups.

This agreement follows a successful collaboration between Merck Serono and Compugen for the discovery of "biomarker signatures" for drug induced toxicity during 2009. Merck Serono and Compugen believe that establishment of Neviah Genomics with the combined capabilities of the two companies could satisfy the growing market need for products to predict toxicity profiles of lead drug candidates at an early stage of development, thereby minimizing attrition and mitigating risk of late-stage drug failure.

Anat Cohen-Dayag, Ph.D., President and CEO of Compugen said, "Following our prior successful collaboration with Merck Serono, we are very pleased to expand this relationship and enter into this new and exciting partnership. We are honored to be the first Israeli company to benefit from the establishment of Merck Serono's Israel Bioincubator and look forward to taking our partnership to the next level." Dr. Cohen-Dayag continued, "Furthermore, the formation of Neviah Genomics on a 'discovery on demand' basis enables Compugen to both continue its focus on therapeutic monoclonal antibodies and therapeutic proteins in the fields of immunology and oncology, and provide potential future benefits for our shareholders from our equity interest in Neviah and royalties from future product sales."

"Neviah Genomics is a perfect illustration of our goals behind the establishment of the Israel Biotech Incubator: to leverage Israeli science and know-how and get access to novel products and technologies for the benefit of Merck Serono's core therapeutic areas," said Susan Herbert, Executive Vice President, Global Business Development and Strategy at Merck Serono. "In this regard, we are delighted to be collaborating on our first investment with Compugen, one of the premier biotech companies in Israel and a world leading predictive drug discovery company. We believe that our joint technology and resources represent a unique basis for a start-up to enter this emerging field that has the potential to significantly reduce the risk of drug discovery and development."

Neviah Genomics will benefit from Compugen's sophisticated proprietary computational discovery platforms to develop advanced toxicogenomics diagnostic tests. Developed tests will be used for the prediction of drug-induced toxicity and integrated into a biomarker platform to support the prioritization and development of drug product candidates.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Drug Candidate Demonstrates High Effectiveness in Type I Diabetes Animal Model
Short-term administration of CGEN-15001 shown to provide long-term prevention of disease development.
Friday, October 11, 2013
Compugen Announces Positive Therapeutic Effects of Novel Peptide in Animal Model of Retinopathy
CGEN-25017, a peptide antagonist predicted using Compugen’s DAC blockers discovery platform, demonstrates significant anti-angiogenic activity.
Thursday, July 23, 2009
Compugen Announces Positive In-Vivo Results for Therapeutic Peptide Candidate for Immune Related Diseases
Data indicates that CGEN-25007 has immunosuppressive effects and therapeutic potential for the treatment of various inflammatory diseases.
Thursday, July 10, 2008
Compugen Announces Discovery of Biomarkers for Early Pre-Clinical Detection of Drug-Induced Kidney Toxicity
Data demonstrate that the biomarker signature may enable a much earlier prediction of drug-induced kidney toxicity during pre-clinical trials.
Monday, June 30, 2008
Scientific News
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Development in Preventing Macular Degeneration
Following macular degeneration insight, promising drugs to prevent vision loss have been identified.
Improving Tumour Therapy with Nanoparticles
UHN nanoparticle called PEARLs is a promising utilisation of photo-thermal therapy for cancer treatment.
New Antidepressant Treatment Discovered
Scientists have demonstrated how gene therapy could lead to new treatments for depression.
Cellular Origin of Skin Cancer Identified
Scientists have identified ‘cell of origin’ in the most common form of skin cancer, and followed the process that leads to tumour growth.
Enhancing Drug Safety with a Web-Based Data Tool
Online and open-access tool allows anyone to find, combine and analyse FDA drug information.
Genetic Missing Link Could Explain Mystery of Heritability
Mother’s diet during pregnancy can permanently affect offspring attributes through process that could be strongly influenced by genetic variation in an unexpected part of the genome.
Does the Transport of Next-Gen Vaccines Lie with E.coli?
Study shows harmless E.coli capsule could aid next-gen vaccine delivery and efficiency.
Breathing in a Cure
Researchers working on inhalable ibuprofen to treat cystic fibrosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!